on ADVICENNE (EPA:ADVIC)
Advicenne Announces 9% Revenue Growth for H1 2025
Advicenne, a French pharmaceutical company specializing in the treatment of rare kidney diseases, has announced revenue of €2.6 million for the first half of 2025. This represents a 9% increase compared to the same period in 2024. Sales of its flagship product, Sibnayal®, reached €1.27 million, an increase of 17%.
In France, this performance was particularly marked, with a 48% increase in Sibnayal® sales. Overall, Sibnayal® sales almost doubled, reaching €5.18 million across all markets.
Advicenne expects to continue its expansion thanks to a strong cash position until the third quarter of 2026, supported by a recent capital increase and a debt restructuring.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ADVICENNE news